| Trial ID: | L1814 |
| Source ID: | NCT04189848
|
| Associated Drug: |
Semaglutide
|
| Title: |
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT04189848/results
|
| Conditions: |
Healthy Volunteers|Diabetes Mellitus, Type 2|Overweight|Obesity
|
| Interventions: |
DRUG: Semaglutide|DRUG: Dulaglutide
|
| Outcome Measures: |
Primary: Intensity of Injection Site Pain, The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed., 1 minute after each injection (Day 1) |
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
104
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-12-03
|
| Completion Date: |
2020-02-27
|
| Results First Posted: |
2021-02-17
|
| Last Update Posted: |
2022-11-07
|
| Locations: |
Novo Nordisk Investigational Site, Groningen, 9728 NZ, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT04189848
|
